Cubist removed from Conviction Buy list at Goldman


Not everyone is excited about the prospects for Cubist's (CBST) acquisition of Optimer (OPTR) and Trius (TSRX). Goldman's Terence Flynn cuts the shares to Neutral from Conviction Buy citing concerns about commercial execution for Dificid and tedizolid. (previous)

From other sites
Comments (1)
  • Ericbo
    , contributor
    Comments (72) | Send Message
     
    It's interesting to note that during the same hour that Goldman downgraded CBST from Conviction Buy to Neutral, Credit Suisse upgraded CBST from Neutral to Outperform because of a positive assessment of the acquisitions and the prospects for their drugs. No wonder we amateur investors are sometimes confused. For what it's worth, it seems that the market today (7/31 at 11:25 AM) tends to go with Credit Suisse's assessment. CBST is up around 12%. I'd be interested in hearing others' observations about this.
    31 Jul 2013, 11:26 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs